- cross-posted to:
- science@lemmy.world
- cross-posted to:
- science@lemmy.world
A Phase 2B trial of 89 adult patients conducted by Melbourne-based MindBio Therapeutics, investigating the effects of microdosing LSD in the treatment of major depressive disorder, found that the psychedelic was actually outperformed by a placebo. Across an eight-week period, symptoms were gauged using the Montgomery-Åsberg Depression Rating Scale (MADRS), a widely recognized tool for the clinical evaluation of depression.
The study has not yet been published. But MindBio’s CEO Justin Hanka recently released the top-line results on his LinkedIn, eager to show that his company was “in front of the curve in microdosing research.”
Most people talking about microdosing are referring to shrooms (psilocybin), not LSD though
Really? I associate it with LSD. Isn’t it more difficult with mushrooms as psilocybin concentration fluctuates? I guess you could extract it. Never really thought about it.
Grind it up and put it in pills. The resulting pills will have approximately the same doses
The fluctuation doesn’t make enough difference to switch between a microdose to a macrodose. But don’t depend on the shake scraps at the bottom of the bag, because that stuff actually can vary wildly
Ime the shroom powder is what can kick your ass the most
I have accidentally BOOMED on the space dust at the bottom of the bag
Microdosing really just refers to taking sub-perceptual amounts of a given substance. It equally applies to things like THC and LSD as it does to shrooms.
Yeah microdosing LSD seems crazy to me because it lasts so much longer than shrooms. When I’ve heard of microdosing it’s usually been referring to shrooms